Prospective Observational Analysis of Circulating Endocan Levels in Patients Presenting With Acute Diverticulitis

N/ANot Yet RecruitingNCT07027007

IRCCS Ospedale San Raffaele60 enrolled

Overview

Quantify the level of endocan in blood samples collected from patients with acute diverticulitis in the emergency department. Determine if endocan levels are correlated with the severity of diverticulitis according to the WSES classification. Assess whether patients requiring emergency surgical intervention have higher endocan values compared to others.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diverticulitis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have signed informed consent * Patients who are affected by acute diverticulitis after clinical evaluation and imaging (i.e. u.s. or CeCT) Exclusion Criteria: * Immunosuppressed patients * Patients suffering chronic inflammatory diseases * Patients with concomitant malignancy, cardiac, renal and haepatic failure * History of major vascular surgery (aneurysmectomy) * Pregnant women * Patients participating in other studies that may interfere with the outcome of the intervention.

Locations (1)

Emergency Department IRCCS San Raffaele

Milan, milano, Italy

Outcomes

Primary Outcomes

Endocan serum level at admission

To evaluate the correlation between blood concentration of endocan and severity of diverticulitis

Time frame: The serum of the patients enrolled inthe study will be collected within two hours from emergency room registation and tested for ENDOCAN

Secondary Outcomes

Predictive value of endocan in determining which patients need emergency surgery

Concentration of endocan in grade 3-4 WSES compared to grade1-2

Time frame: Patients will undergo diverticulitis evaluations (per WSES criteria) within 3 hours of Emergency room admission and study enrollment

Prognostic value of endocan in determining the risk of recurrent diveritculitis

Concentration of endocan in patient who develop a recurrence after 1 year follow-up

Time frame: From discharge after definitive tretament till 12 months follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.